Nachrichten zur Abbvie Inc. Aktie

Are Options Traders Betting on a Big Move in AbbVie (ABBV) Stock?

Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.…

Forget Nvidia, Buy This Magnificent Healthcare Stock Instead

AbbVies returns havent been great this year, but investors shouldnt overlook this promising growth stock.…

CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law to Discuss Your Rights

NEW YORK, May 25, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating…

BaseLaunch geht Partnerschaft mit AbbVie ein

Basel - Der Basler Accelerator und Inkubator BaseLaunch, der neue Biotechfirmen in ihrer Frühphase finanziert und unterstützt, hat den US-Pharmakonzern…

BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by AbbVie, Contact the Firm for Details

NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Bleichmar Fonti & Auld LLP is investigating the merger between…

[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

AbbVie-Aktie mit leichten Kursgewinnen (152,8600 €)

Im Plus liegt zur Stunde die AbbVie-Aktie . Zuletzt zahlten Investoren für die Aktie 166,22 US-Dollar. Freuen können sich gegenwärtig…

Non Hodgkin Lymphoma (NHL) Global Market Report 2024: Asia-Pacific Set for Swift Growth Amidst Advancements in Immunotherapy and Diagnostic Tools

Dublin, May 17, 2024 (GLOBE NEWSWIRE) -- The "Non Hodgkin Lymphoma (NHL) Global Market Report 2024" report has…

Pharmalittle: Were reading about fake studies, AbbVie investing in psychedelics, and more

Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost…

AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal

AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.…

Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJs New Plan to Resolve Talc Claims

Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.…

Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors

AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Groups CEO will testify…

AbbVie investiert rund 150 Millionen Euro in die Zukunft der Spitzenforschung am Standort Ludwigshafen

AbbVie Deutschland GmbH & Co. KG: Ludwigshafen (ots) - - Modernste Rahmenbedingungen für Forscher*innen im Kampf gegen u.a. Alzheimer und…

AbbVie: Diversifizierung auf Schiene - Aktienanalyse

Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…

AbbVie (ABBV) Q1 2024 Earnings Call Transcript

ABBV earnings call for the period ending March 31, 2024.…

AbbVie Inc. (ABBV) Q1 2024 Earnings Call Transcript

…

Jim Cramers quick thoughts on 5 stocks: Chevron, Snap, Intel, AbbVie and Colgate

Jim Cramer offers his take on companies outside the CNBC Investing Club’s portfolio.…

AbbVie Beats Quarterly Views As Skyrizi Nearly Snags Humiras Title

Skyrizi brought in $2.01 billion in sales, just barely trailing the $2.27 billion generated by the struggling Humira.…

AbbVie lifts profit forecast after Skyrizi sales beat expectations

…

AbbVie raises annual profit forecast on strong Skyrizi sales By Reuters

AbbVie raises annual profit forecast on strong Skyrizi sales…

AbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up By Investing.com

AbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up…

AbbVie earnings beat by $0.04, revenue topped estimates By Investing.com

AbbVie earnings beat by $0.04, revenue topped estimates…

AbbVie reports positive results from Rinvoq versus Dupixent study

…

Weight Loss Drugs Market Trends Analysis 2018-2023 and Opportunities Forecast 2024-2033 Featuring Pfizer, Roche, Merck & Co, AbbVie, and Novartis

Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Weight Loss Drugs Global Market Report 2024" report has been…

4 Large Drug Stocks to Hold on to Amid Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk…

AbbVie (ABBV) to Report Q1 Earnings: Whats in the Cards?

Investor focus is likely to be on the sales of AbbVies (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it…

AbbVie Q1 Earnings Preview: No Repeat Of Last Years Q1 Disappointment

…

AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition

…

AbbVie keeps Humira market share near 100% despite biosimilars: report

…

Dividendenbekanntmachungen (12.04.2024)

Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBVIE INC US00287Y1091 1,55 USD 1,4449 EUR AMERICAN EQUITY INVESTMENT LIFE HOLDING ... US0256762065…

The Zacks Analyst Blog Highlights AbbVie, Salesforce, General Electric, The TJX Companies and UBS Group

AbbVie, Salesforce, General Electric, The TJX Companies and UBS Group are part of the Zacks top Analyst Blog.…

Top Stock Reports for AbbVie, Salesforce & General Electric

Todays Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Salesforce, Inc. (CRM) and General…

AbbVie: Still Fits Buffetts 10x EBT Rule Well Despite Guidance Revision

…

Pfizer: AbbVie, Bristol-Myers, Eli Lilly, Johnson & Johnson, Takeda - Die Konkurrenz ist enorm - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Pfizer-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Pfizer Inc. (ISIN: US7170811035,…

AbbVie slips after revising guidance to reflect earnings impact

…

Landos Biopharma stock downgraded at H.C. Wainwright amid AbbVie acquisition By Investing.com

Landos Biopharma stock downgraded at H.C. Wainwright amid AbbVie acquisition…

Pharma Stock Roundup: ABBV & NVOs New M&As, FDA Nod to JNJ & MRK PAH Drugs

While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves…

[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

dpa-AFX ProFeed